Insider Transactions in Q4 2023 at Supernus Pharmaceuticals, Inc. (SUPN)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 22
2023
|
Jack A. Khattar President, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,958
-1.34%
|
$322,866
$27.66 P/Share
|
|
Dec 22
2023
|
Jack A. Khattar President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+2.72%
|
-
|
|
Dec 22
2023
|
Jonathan Rubin SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
204
-5.92%
|
$5,508
$27.66 P/Share
|
|
Dec 22
2023
|
Jonathan Rubin SVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+14.83%
|
-
|
|
Nov 16
2023
|
Charles W Newhall Iii Director |
SELL
Open market or private sale
|
Direct |
2,500
-2.09%
|
$70,000
$28.01 P/Share
|
|
Nov 16
2023
|
Charles W Newhall Iii Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,457
+5.87%
|
$67,113
$9.24 P/Share
|
|
Nov 15
2023
|
Frederick M. Hudson Director |
SELL
Open market or private sale
|
Direct |
9,093
-11.36%
|
$254,604
$28.5 P/Share
|
|
Nov 15
2023
|
Frederick M. Hudson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,457
+14.98%
|
$67,113
$9.24 P/Share
|
|
Nov 14
2023
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
SELL
Open market or private sale
|
Direct |
1,110
-16.35%
|
$31,080
$28.13 P/Share
|
|
Nov 14
2023
|
Frank Mottola SVP, Quality, GMP, Ops, IT |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+22.75%
|
$18,000
$9.24 P/Share
|
|
Oct 13
2023
|
Timothy C Dec Senior Vice-President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,911
-27.3%
|
$49,686
$26.91 P/Share
|
|
Oct 13
2023
|
Timothy C Dec Senior Vice-President & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+36.36%
|
-
|